These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34639851)

  • 21. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Point-of-sale marketing of heated tobacco products in Israel: cause for concern.
    Halpern-Felsher B
    Isr J Health Policy Res; 2019 May; 8(1):47. PubMed ID: 31133053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Investigation of Influential Users in the Promotion and Marketing of Heated Tobacco Products on Instagram: A Social Network Analysis.
    Gu J; Abroms LC; Broniatowski DA; Evans WD
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Social Media Discussions on the FDA's Modified Risk Tobacco Product Authorization of IQOS.
    Jun J; Zhang N; Zain A; Mohammadi E
    Subst Use Misuse; 2022; 57(3):472-480. PubMed ID: 34986075
    [No Abstract]   [Full Text] [Related]  

  • 26. Anticipating IQOS market expansion in the United States.
    Abroms L; Levine H; Romm K; Wysota C; Broniatowski D; Bar-Zeev Y; Berg C
    Tob Prev Cessat; 2022; 8():04. PubMed ID: 35174298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland.
    Hair EC; Bennett M; Sheen E; Cantrell J; Briggs J; Fenn Z; Willett JG; Vallone D
    Tob Control; 2018 Nov; 27(Suppl 1):s70-s73. PubMed ID: 29764957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure to IQOS ads and reduced exposure claims, and association with perceived risk from COVID-19 on IQOS purchase and use intentions: results from a web-based survey.
    Sharma A; Fix B; Hyland A; Bansal-Travers M; Quisenberry A; O'Connor R
    Front Public Health; 2023; 11():1307484. PubMed ID: 38269390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do Young Adults Attend to Health Warnings in the First IQOS Advertisement in the U.S.? An Eye-Tracking Approach.
    Liu J; Phua J; Krugman D; Xu L; Nowak G; Popova L
    Nicotine Tob Res; 2021 May; 23(5):815-822. PubMed ID: 33245339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marketing IQOS in a dark market.
    Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
    Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel.
    Khayat A; Levine H; Berg CJ; Abroms LC; Duan Z; Wang Y; LoParco CR; Elbaz D; Cui Y; Bar-Zeev Y
    Res Sq; 2024 Mar; ():. PubMed ID: 38464035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Industry marketing of tobacco products on social media: case study of Philip Morris International's IQOS.
    Abroms LC; Wysota CN; Tosakoon S; Khayat A; Duan Z; Bar-Zeev Y; Berg CJ; Levine H
    Tob Control; 2024 Jun; 33(4):518-524. PubMed ID: 36927516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Categorizing IQOS-Related Twitter Discussions.
    Barker JO; Vassey J; Chen-Sankey JC; Allem JP; Cruz TB; Unger JB
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33946546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heated tobacco product regulation under US law and the FCTC.
    Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proximity of IQOS and JUUL points of sale to schools in Israel: a geospatial analysis.
    Elbaz D; Bar Zeev Y; Berg CJ; Abroms LC; Levine H
    Tob Control; 2022 Dec; 31(e2):e156-e161. PubMed ID: 34753792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smokers' Exposure to Perceived Modified Risk Claims for E-Cigarettes, Snus, and Smokeless Tobacco in the United States.
    Wackowski OA; O'Connor RJ; Pearson JL
    Nicotine Tob Res; 2021 Feb; 23(3):605-608. PubMed ID: 32812028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
    Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
    Tob Control; 2023 Mar; ():. PubMed ID: 36958825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.